Promise of epigenetic modulation as a target in atherosclerotic patients
This lecture was part of a CME accredited symposium: Managing Diabetes & CVD: Is epigenetics a new way forward? held at ESC 2017 in Barcelona
Video navigation menu
The prominent role of inflammation in atherogenesis 0:29
How to target the inflammatory processes with therapy? 3:01
What happens at the DNA/chromatin level during epigenetic gene regulation? 5:24
Aberrant epigenetic modifications in atherosclerotic disease 7:52
Experimental results with interfering with epigenetic processes 10:16
Educational information
The educational objectives of this symposium were to:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Faculty
Erik Stroes, MD, is Internist Vascular Medicine, Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
CME Accreditation
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Disclosures
This symposum was supported by an unrestricted educational grant provided by Resverlogix
Online-CME
This is available as accredited online CME for members. Click the button below to enroll:
EnrollThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: